FSUE Moscow Endocrine Plant took part in the scientific and practical forum “Russian Health Week 2018”.
The exposition of the Enterprise was presented at the exhibition stand of the Ministry of Industry and Trade of Russia.
Along with traditionally produced products of social importance, the latest developments of the Moscow Endocrine Plant were presented, implemented, inter alia, within the framework of the roadmap approved by the Decree of the Government of the Russian Federation from July 1, 2016 No. 1403 "Improvement of the availability of narcotic drugs and psychotropic substances for medical use”.
This year, the nomenclature of the Enterprise was replenished with the first Russian generics - Lornoxicam, a modern drug in the group of non-steroidal anti-inflammatory drugs and Oxybuprocaine, a drug for ophthalmology. It is important to emphasize that both drugs are included in the list of Vital and Essential Drugs.
The participants and guests of the forum were particularly interested in the departmental project on organization of full-cycle production in Russia - from API to finished dosage forms, in the Bryansk region (Pochep).
Comment type is not specified in the component properties.